Details of Drug-Drug Interaction
| Drug General Information (ID: DDIBFY1XE3) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Dexlansoprazole | Drug Info | Selpercatinib | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Proton Pump Inhibitors | Antineoplastics | |||||||
| Structure | |||||||||
| Mechanism of Dexlansoprazole-Selpercatinib Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Altered gastric pH Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Dexlansoprazole | Selpercatinib | |||||||
| Mechanism | Gastric alkalinizer | Gastric pH sensitive | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Gastric pH | ||||||||
| Factor Description | The normal pH range of gastric acid is between 1.5 and 3.5 and is highly acidic, consisting mainly of hydrochloric acid. Changes in the pH of the stomach can alter the absorption of drugs. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Concomitant use of selpercatinib with proton pump inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends taking selpercatinib with food to minimize the clinical impact of the interaction. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||||||||||||||||
| 2 | Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN. | ||||||||||||||||||